Current Portfolio
AC Immune SA (NASDAQ: ACIU)
is clinical-stage biopharmaceutical company, is a global leader in developing precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and certain rare indications.
Lausanne, Switzerland
Achilles Therapeutics plc (NASDAQ: ACHL)
is a biopharmaceutical company developing precision T cell therapies that target clonal neoantigens.
London, UK
Adaptimmune therapeutics plc (NASDAQ: ADAP)
is a leader in TCR T-cell therapy focused on designing and delivering novel cancer immunotherapy products. Adaptimmune has acquired TCR² Therapeutics in June 2023.
Oxfordshire, UK
Akero Therapeutics, INc. (NASDAQ: AKRO)
is a clinical-stage company dedicated to developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis, or MASH, formerly known as non-alcoholic steatohepatitis, or NASH, a disease without any approved therapies.
South San Francisco, CA
Allakos Inc (Nasdaq: allk)
is a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States.
San Carlos, CA
Amygdala neurosciences
is focused on addressing the growing unmet need associated with substance use disorder by discovering, developing and commercializing safe and effective pharmacotherapies to treat and prevent addiction.
San Francisco, CA
Angarus Therapeutics, inc
is developing checkpoint blockers on the innate immunity STING pathway.
Sunnyvale, CA
ARDELYX, INC (NASDAQ: ARDX)
is committed to bringing effective medicines with distinct safety and dosing advantages to underserved patients by using the gut as the gateway to better health.
Fremont, CA
Autolus Therapeutics Plc (NASDAQ: AUTL)
is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer.
London, UK
Axsome Therapeutics, Inc (NASDAQ: AXSM)
is commercial-stage biopharmaceutical company developing and delivering novel therapies for central nervous system, or CNS, conditions that have limited treatment options. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate.
New Yorrk, NY
BOLT BioTherapeutics, Inc (NASDAQ: BOLT)
is clinical-stage biotechnology company engaged in the development of immuno-oncology agents to target tumor cells for elimination by the immune system.
Redwood City, CA
Cessation therapeutics, INC
is a pre-clinical stage company focused on research and development of therapeutics designed to treat nicotine, opioid and other substance use disorders.
Dallas, TX
CORVUS PHARMACEUTICALS, INC (NASDAQ: CRVS)
is a clinical-stage biopharmaceutical company focused on the development of novel agents that target the immune system to treat patients with cancer.
Burlingame, CA
CYTOMX Therapeutics, Inc (NASDAQ: CTMX)
is a clinical-stage, oncology-focused biopharmaceutical company advancing potential first-in-class and best-in-class antibody-based therapeutics created using its Probody® therapeutic technology platform that could meaningfully improve outcomes for cancer patients.
South San Francisco, CA
Deciphera Pharmaceuticals, INC (NASDAQ: DCPH)
is developing novel drug candidates to improve the lives of cancer patients by addressing key mechanisms of tumor and drug resistance that limit the effectiveness of many cancer therapies.
Deciphera is currently being acquired by ONO Pharmaceutical Co, Ltd. for $2.4 billion.
Waltham, MA
DIALECTIC THERAPEUTICS, INC
is a biotechnology company dedicated to the development of unique, impactful anti-cancer drugs that effectively treat patients with few to no other options.
Dallas, TX
Hinge bio, inc
is leveraging its proprietary Flex-Hinge antibody platform to develop the next-generation of bispecific and multispecific antibodies that bind with multi-handed cooperativity to both disease targets and effector cells.
Burlingame, CA
Inventiva S.A. (NASDAQ: IVA)
is clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
France
IO Biotech, Inc (NASDAQ: IOBT)
is a clinical-stage biotechnology company dedicated to the identification and development of disruptive immune therapies for the treatment of cancer.
Copenhagen, Denmark
IOVANCE Biotherapeutics, Inc (NASDAQ: IOVA)
is a clinical-stage biotechnology company focused on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.
San Carlos, CA
MeiragTx HOldings plc (Nasdaq: MGTX)
is a clinical-stage gene therapy company focused on developing treatments for patients with serious diseases.
New York, NY
Personalis, Inc (NASDAQ: PSNL)
is a cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response.
Menlo Park, CA
Pliant therapeutics, inc (NASDAQ: PLRX)
is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
South San Francisco, CA
Praxis Precision Medicines, INc (NASDAQ: PRAX)
is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.
Boston, MA
Regenxbio, Inc (NASDAQ: RGNX)
is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.
Rockville, MD
RIBOSCIENCE LLLC
applies specialized chemistry and biology to create novel treatments for human diseases.
Sunnyvale, CA
Solid Biosciences, INc (NASADAQ: SLDB)
is a life science company focused on developing transformative treatments to improve the lives of patients living with Duchenne Muscular Dystrophy.
Cambridge, MA
Ventyx Biosciences, Inc (NASDAQ: VTYX)
is clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases.
San Diego, CA
ScyNEXIS, Inc (NASDAQ: SCYX)
is a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections.
Jersey City, NJ
Past Investments
CARA THERAPEUTICS, INC (NASDAQ: CARA)
is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).
Stamford, CT
chemocentryx, inc (nasdaq: CCXI)
is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, primarily focused on orphan and rare diseases.
ChemoCentryx has been acquired by Amgen (NASDAQ: AMGN) for $4 billion in cash in October 2022.
San Carlos, CA
CONTRAFECT CORPORATION (NASDAQ: CFRX)
is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings.
Yonkers, NY
CymaBay Therpaeutics, Inc (NASDAQ: CBAY)
is a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.
CymaBay has been acquired by Gilead for $4.3 billion in March 2024.
Newark, CA
FATE THERAPEUTICS, INC (NASDAQ: FATE)
is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders.
San Diego, CA
Galera Therapeutics, Inc (NASDAQ: GRTX)
is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer.
Malvern, PA
HERON Therapeutics, INC (NASDAQ: HRTX)
aims to build on therapeutics with well-known pharmacology by improving their safety and efficacy as well as broadening their potential field of use.
San Diego, CA
IMMUNE DESIGN CORP (NASDAQ: IMDZ)
is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease.
Immune Design was acquired in April 2019 by Merck (NYSE: MRK) for $300 million.
Seattle, WA
Inflarx n.v. (NASDAQ: IFRX)
is focused on applying their proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a.
Jena, Germany
Intra-Cellular Therapies Inc (NASDAQ: ITCI)
is focused on developing innovative treatments to improve the lives of individuals suffering from neuropsychiatric and neurologic disorders, in order to reduce the burden on patients and their caregivers.
New York, NY
Iveric BIO, Inc (NASDAQ: ISEE)
is a biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with significant unmet medical needs.
Iveric Bio has been acquired by Astellas for $5.9 billion in July 2023.
Parsippany, NJ
Jounce therapeutics, Inc (NASDAQ: JNCE)
is focused on developing unparalleled immunologic insights into tumors in order to match the right therapies to the right patients.
Cambridge, MA
KADMON Holdings, INC (NYSE: KDMN)
is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs.
Kadmon was acquired by Sanofi (NASDAQ:SNY) for $1.9 Billion.
New York, NY
Krystal Biotech, Inc (NASDAQ: KRYS)
is a clinical-stage biotechnology company leading the field of redosable gene delivery for the treatment of serious rare diseases.
Pittsburgh, PA
Mirati Therapeutics, inc (Nasdaq: mrtx)
is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer.
Mirati was acquired in January 2024 by Bristol Myers Squibb (NYSE: BMY) for up to $5.8 million.
San Diego, CA
MONOGRAM BIOSCIENCES, INC (NASDAQ: MGRM)
(FORMERLY VIROLOGIC, INC)
blends the high-quality pathology of academic-based centers with the personal service of a local pathologist.
In June 2009, Monogram was acquired by LabCorp for $107 Million.
South San Francisco, CA
NOVAVAX, INC (NASDAQ: NVAX)
is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases.
Gaithersburg, MD
Orchard Therpaeutics plc (NASDAQ: ORTX)
is a global gene therapy company dedicated to transforming the lives of people affected by severe diseases through the development of innovative, potentially curative gene therapies.
Orchard is currently being acquired by Kyowa Kirin for up to $478 million.
London, United Kingdom
Provention bio, inc. (NASDAQ: prvb)
is a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases.
Provention Bio has been acquired by Sanofi for $2.9 billion in April 2023.
Red Bank, NJ
Puma Biotechnology, Inc (NASDAQ: PBYI)
is a biopharmaceutical company focused on the development and commercialization of products to enhance cancer care in the United States and internationally.
Los Angeles, CA
RAPTOR PHARMACEUTICALS CORP (NASDAQ: RPTP)
is focused on identifying and developing differentiated and accessible medicines that address unmet medical needs.
In October 2016, Raptor was acquired by Horizon Pharma (Nasdaq: HZNP) for $800 Million.
Novato, CA
RELYPSA, INC (NASDAQ: RLYP)
is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening.
In September 2016, Relypsa was acquired by Galencia for $1.5 billion.
Redwood City, CA
Silverback therapeutics, inc (NASDAQ: SBTX)
is a biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases.
Seattle, WA
STEMCENTRIX, INC
is dedicated to making a remarkable impact for cancer patients. Stemcentrx develops therapies and diagnostics for cancer patients.
Stemcentrx was acquired by AbbVie (NYSE: ABBV) in 2016 for $5.8 billion.
South San Francisco, CA
TCR² Therapeutics, Inc (NASDAQ: TCRR)
is a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. TCR² was acquired by Adaptimmune Therapeutics in June 2023.
Cambridge, MA
Urogen Pharma, ltd (NASDAQ: URGN)
is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options.
Princeton, NJ
XENOPORT, INC (NASDAQ: XNPT)
is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders.
Xenoport was acquired by Arbor Pharmaceuticals, LLC in July 2016 for $467 million.
Santa Clara, CA
XERIS PHARMACEUTICALS, INC (NASDAQ: XERS)
is dedicated to the development of ready-to-use, room-temperature stable injectable and infusible drug formulations that offer distinct advantages over conventional product formulations.
Chicago, IL